Currently, there are multiple clinical trials exploring the feasibility of MAT2A inhibitors and FAK inhibitors as therapeutic options [37, 38]; however, discovery of MATα2-t and the novel application of neutralizing MATα2 antibody as a new therapeutic could possibly have wider applicability with less toxicity as it is only targeting MATα2-t, which seems to only be vital to cancer cell survival. The gene discussed is MAT2A; the disease is cancer.